PF-114, A NOVEL SELECTIVE PAN BCR/ ABL INHIBITOR FOR PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) LEUKEMIA, EFFECTIVELY TARGETS T315I AND THE OTHER RESISTANCE MUTANTS

被引：0
|
作者：
Mian, A. [1 ]
Badura, S. [1 ]
Rafiei, A. [1 ]
Metodieva, A. [1 ]
Zeifman, A. [2 ]
Titov, I. [2 ]
Stroylov, V. [2 ]
Stroganov, O. [2 ]
Novikov, F. [3 ]
Ottmann, O. [1 ]
Chilov, G. [2 ]
Ruthardt, M. [1 ]
机构：
[1] Goethe Univ, Hematol, Frankfurt, Germany
[2] Fus Pharma LLC, Moscow, Russia
[3] Fus Pharma LLC, Moscow, Russia
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S1177
引用
收藏
页码：488 / 489
页数：2
相关论文
共 37 条
  • [1] PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph plus ) leukemias harboring the T315I mutation
    Mian, A. A.
    Rafiei, A.
    Haberbosch, I.
    Zeifman, A.
    Titov, I.
    Stroylov, V.
    Metodieva, A.
    Stroganov, O.
    Novikov, F.
    Brill, B.
    Chilov, G.
    Hoelzer, D.
    Ottmann, O. G.
    Ruthardt, M.
    LEUKEMIA, 2015, 29 (05) : 1104 - 1114
  • [2] PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation
    A A Mian
    A Rafiei
    I Haberbosch
    A Zeifman
    I Titov
    V Stroylov
    A Metodieva
    O Stroganov
    F Novikov
    B Brill
    G Chilov
    D Hoelzer
    O G Ottmann
    M Ruthardt
    Leukemia, 2015, 29 : 1104 - 1114
  • [3] The ''Gatekeeper'' Mutation T315I in BCR/ABL Confers Additional Oncogenic Activities to Philadelphia Chromosome Positive Leukemia
    Zafar, Usva
    Yusuf, Mohammed
    Chakraborty, Rikhia
    Lalani, El-Nasir M. A.
    Mian, Afsar Ali
    BLOOD, 2019, 134
  • [4] A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia
    Seymour, J. F.
    Kim, D. W.
    Rubin, E.
    Haregewoin, A.
    Clark, J.
    Watson, P.
    Hughes, T.
    Dufva, I.
    Jimenez, J. L.
    Mahon, F-X
    Rousselot, P.
    Cortes, J.
    Martinelli, G.
    Papayannidis, Cristina
    Nagler, A.
    Giles, F. J.
    BLOOD CANCER JOURNAL, 2014, 4 : e238 - e238
  • [5] A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia
    J F Seymour
    D W Kim
    E Rubin
    A Haregewoin
    J Clark
    P Watson
    T Hughes
    I Dufva
    J L Jimenez
    F-X Mahon
    P Rousselot
    J Cortes
    G Martinelli
    C Papayannidis
    A Nagler
    F J Giles
    Blood Cancer Journal, 2014, 4 : e238 - e238
  • [6] Inhibition of T315I Bcr-Abl and other imatinib-resistant Bcr-Abl mutants by the selective Abl kinase inhibitor SGX70393.
    O'Hare, Thomas
    Eide, Christopher A.
    Tyner, Jeffrey W.
    Wong, Matthew J.
    Smith, Caitlyn A.
    Corbin, Amie S.
    Buchanan, Sean
    Jessen, Katayoun A.
    Tang, Crystal
    Holme, Kevin
    Burley, Stephen K.
    Deminger, Michael W. N.
    BLOOD, 2006, 108 (11) : 400A - 401A
  • [7] The tyrosine kinase inhibitor axitinib targets T315I gatekeeper-mutant Philadelphia chromosome-positive leukemias in vitro and in vivo
    Pemovska, Tea
    Kontro, Mika
    Repasky, Gretchen A.
    Porkka, Kimmo
    Wennerberg, Krister
    CANCER RESEARCH, 2014, 74 (19)
  • [8] Justification for Asciminib Dosing in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph plus CML-CP) with and without the T315I Mutation
    Combes, Francois Pierre
    Li, Ying Fei
    Sy, Sherwin K. B.
    Lorenzo, Sebastien
    Dasgupta, Kohinoor
    Kapoor, Shruti
    Hoch, Matthias
    Ho, Yu-Yun
    BLOOD, 2022, 140 : 6791 - 6792
  • [9] T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system
    Tamai, Minori
    Inukai, Takeshi
    Kojika, Satoru
    Abe, Masako
    Kagami, Keiko
    Harama, Daisuke
    Shinohara, Tamao
    Watanabe, Atsushi
    Oshiro, Hiroko
    Akahane, Koshi
    Goi, Kumiko
    Sugihara, Eiji
    Nakada, Shinichiro
    Sugita, Kanji
    SCIENTIFIC REPORTS, 2018, 8
  • [10] Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system
    Thao T. T. Nguyen
    Minori Tamai
    Daisuke Harama
    Keiko Kagami
    Shin Kasai
    Atsushi Watanabe
    Koshi Akahane
    Kumiko Goi
    Takeshi Inukai
    International Journal of Hematology, 2022, 116 : 534 - 543
1234